Plant Name: Piper longum
Taxonomic Information:
Plant ID: NPO26237
Plant Latin Name: Piper longum
Taxonomy Genus: Piper
Taxonomy Family: Piperaceae
Plant External Links:
NCBI TaxonomyDB:
49511
Plant-of-the-World-Online:
682031-1
Used in Medicines:
Country/Region:
Jordan; Iraq; India; China; ThailandTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMGeographical Distribution:
Bangladesh; Nepal; India; Vietnam; Jordan; Thailand; Sri Lanka; China; Iraq
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| HTR2C; | |
| TRPV1; | |
| MAOB; | |
| ALDH1A1; HPGD; SOAT1; | |
| TP53; | |
| MAPT; MITF; RAB9A; NPC1; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | SOAT1 | Acyl coenzyme A:cholesterol acyltransferase 1 | P35610 | CHEMBL2782 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | MITF | Microphthalmia-associated transcription factor | O75030 | CHEMBL1741165 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.374E-06 | 2.158E-02 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 5.272E-06 | 2.170E-02 | MAPT, TP53, TRPV1 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 5.980E-06 | 2.170E-02 | CYP1A2, HPGD, MAOB, NPC1, TRPV1, TSHR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.428E-06 | 2.335E-02 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 1.042E-05 | 2.335E-02 | CYP1A2, HPGD, MAOB, NPC1, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.179E-05 | 2.335E-02 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 3.730E-05 | 3.955E-02 | CYP3A4, NPC1, SOAT1 |
| MF | GO:0005488; binding | GO:0050662; coenzyme binding | 4.712E-05 | 4.276E-02 | ALDH1A1, HPGD, MAOB, SOAT1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.450E-05 | 6.336E-04 | CYP1A2, ALDH1A1, CYP3A4 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.736E-05 | 6.336E-04 | MAOB, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.028E-04 | 7.352E-03 | MAOB, CYP1A2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.107E-04 | 5.127E-03 | CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.057E-03 | 1.221E-02 | HTR2C, TRPV1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.266E-03 | 1.221E-02 | MITF, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.471E-04 | 1.221E-02 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.394E-03 | 1.747E-02 | HTR2C, TRPV1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.338E-03 | 1.221E-02 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.684E-03 | 1.366E-02 | CYP1A2, CYP3A4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR2C; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAOB; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOB; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR2C; TRPV1; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | TRPV1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; |
| NA: NA | Esophagus sensitivity | NA | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | MAOB; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAOB; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1; |
| NA: NA | Motor symptoms | NA | MAOB; |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB; |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C; MAOB; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; HTR2C; MAOB; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
